Aphranel Announces EU Certification and New Innovations
References: christabellescloset
Aphranel is a regenerative aesthetics brand based in Shanghai, and recently, it marked its first anniversary by announcing a number of developments.
For one, the company received European Union Medical Device Regulation certification for its Calcium Hydroxyapatite Microsphere Injectable Facial Filler. It also launched a second product called MagicCrystal Arc for facial contouring. Aphranel also noted it has delivered over 150,000 syringes across China within its first 12 months on the market.
The company’s original CaHA filler received China’s first Class III approval for such a product in May 2025, and the newly obtained EU MDR certification, granted after two years and seven months of review involving more than 6,300 pages of technical documentation and over 120 internal regulatory meetings, makes Aphranel the first China-originated and China-manufactured facial injectable filler to achieve this designation, as well as the first CaHA microsphere filler from the Asia-Pacific region certified under the EU MDR framework.
Image Credit: Aphranel
For one, the company received European Union Medical Device Regulation certification for its Calcium Hydroxyapatite Microsphere Injectable Facial Filler. It also launched a second product called MagicCrystal Arc for facial contouring. Aphranel also noted it has delivered over 150,000 syringes across China within its first 12 months on the market.
The company’s original CaHA filler received China’s first Class III approval for such a product in May 2025, and the newly obtained EU MDR certification, granted after two years and seven months of review involving more than 6,300 pages of technical documentation and over 120 internal regulatory meetings, makes Aphranel the first China-originated and China-manufactured facial injectable filler to achieve this designation, as well as the first CaHA microsphere filler from the Asia-Pacific region certified under the EU MDR framework.
Image Credit: Aphranel
Trend Themes
-
Regenerative Injectables — Calcium hydroxyapatite microsphere fillers signal a shift toward longer-lasting aesthetic treatments that blend cosmetic enhancement with tissue-supportive regenerative mechanisms.
-
Certified Chinese Medtech — EU MDR approval for China-originated devices reflects rising global credibility for Asian manufacturers in premium, highly regulated medical aesthetics markets.
-
Facial Contouring Innovation — New contouring-focused filler lines highlight demand for minimally invasive products that deliver structural definition without surgical procedures.
Industry Implications
-
Medical Aesthetics — Premium injectable platforms are reshaping clinic offerings through science-backed products that combine visible results with stronger regulatory validation.
-
Medical Devices — Stringent certification pathways create differentiation for manufacturers that build deep clinical, technical, and compliance documentation into product development.
-
Cosmetic Dermatology — High-volume adoption of advanced fillers points to expanding patient interest in non-surgical facial rejuvenation across dermatology and aesthetic practices.
8.3
Score
Popularity
Activity
Freshness
